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1 It has been proposed that pentoxifylline (PTF) acts an antifibrogenic agent by reducing the synthesis
of extracellular matrix components, and this possibility has been confirmed in animal models of hepatic
fibrosis. In this study the effects of PTF on the proliferation of extracellular matrix producing cells
induced by platelet-derived growth factor (PDGF) were evaluated. The study was performed on hepatic
stellate cells, currently indicated as the major source of extracellular matrix in fibrotic liver.
2 PTF caused a dose-dependent reduction of PDGF-induced mitogenesis with an IC50 of 170 gM,
identical to the EC50 for the increase in intracellular cyclic AMP levels. Preincubation with PTF did not
affect either PDGF-receptor autophosphorylation or phosphotidylinositol 3-kinase activity, whereas it
markedly reduced PDGF-stimulated extracellular signal-regulated kinase (ERK) activity and ERK
isoform phosphorylation. PTF also reduced PDGF-induced c-fos mRNA expression, which is dependent
on activation of the RAS/ERK pathway. In addition, the PDGF-induced increase in cytsolic-free
calcium was almost completely prevented by pretreating the cells with PTF.
3 The results of the present study indicate that PTF, in addition to its effect on collagen deposition and
degradation, may exert an antifibrogenic effect by reducing the PDGF-induced proliferation of
extracellular matrix producing cells. This effect appears to be mediated by a reduction of PDGF-
stimulated ERK activity as well as of other intracellular signalling pathways such as the PDGF-induced
elevation of cytosolic-free calcium.
Keywords: Cyclic AMP; extracellular-signal regulated kinase (ERK); hepatic fibrosis; hepatic stellate cells (HSCs); intracellular
calcium; mitogen-activated protein kinase (MAPK); pentoxifylline; platelet-derived growth factor (PDGF);
phosphatidylinositol 3-kinase (PI 3-K)
Introduction
Several in vitro and in vivo studies have shown that hepatic
stellate cells (HSCs, also known as Ito cells, fat-storing cells or
lipocytes), liver-specific pericytes, play a fundamental role in
the progression of liver fibrogenesis (for review see: Friedman,
1993; Pinzani, 1995). Indeed, in conditions of chronic liver
tissue damage and inflammation, HSCs undergo a process of
activation and phenotypical modulation leading to cell pro-
liferation and to a remarkable increase in their synthetic rate of
extracellular matrix components, particularly collagen type I
and type III. Among other polypeptide growth factors po-
tentially involved in chronic tissue inflammation, platelet-de-
rived growth factor (PDGF), a dimer of two polypeptide
chains referred to as A- and B-chain, has been shown to be the
most potent mitogen for cultured HSCs isolated from rat,
mouse, or human liver (Pinzani et al., 1989; 1992a; 1995) and,
importantly, codistribution of PDGF with cells expressing the
relative receptor subunits (termed a and )) has been clearly
demonstrated following both acute and chronic liver tissue
damage (Pinzani et al., 1994; 1996), thus confirming a func-
tional role of this polypeptide mitogen in the tissue repair
process and in the development of hepatic fibrosis.
Pentoxifylline (PTF), a trisubstituted xanthine-derived
phosphodiesterase inhibitor, is currently used in the treatment
of peripheral vascular disorders because of its effects on ery-
throcyte deformability and tissue oxygen delivery (Ward &
Clissold, 1987). In vitro studies, performed in cultured dermal
fibroblasts, have suggested that PTF may exert an anti-
fibrogenic effect by reducing the synthesis of extracellular
matrix (ECM) components, including collagen type I and type
III, by increasing collagenase activity, and by decreasing cell
proliferation (Berman et al., 1989; Chang et al., 1993; Duncan
et al., 1995).
Although PTF has been shown to dose-dependently reduce
PDGF-induced DNA synthesis in dermal fibroblasts (Pe-
terson, 1993), it is unknown whether this effect could be re-
levant in antagonizing the proliferative effect ofPDGF on cells
primarily involved in the progression of liver fibrogenesis, i.e.
activated HSCs. This issue becomes even more relevant after
the recent demonstration of a possible antifibrogenic effect of
PTF in two animal models of hepatic fibrosis: the yellow
phosphorus porcine model (Peterson, 1993) and the rat bile
duct ligation and scission model (Boigk et al., 1995).
The present study was specifically designed in order to
evaluate the effect of PTF on PDGF-induced cell proliferation
in HSCs isolated from normal human liver and activated in
culture, and to establish at which level PTF may interact with
the complex cascade of intracellular signalling events leading
to cell proliferation elicited by PDGF-receptor physical asso-
ciation with signalling molecules (Claesson-Welsh, 1994). The
phosphotyrosines on the activated receptor operate as high-
affinity binding sites for several molecules involved in down-
stream transmission of the signal through binding to src-
homology-2 (SH-2) domains or phosphotyrosine-binding do-
mains (Cohen et al., 1995; Pawson, 1995). In particular, the
attention was focused on PDGF-induced activation of three
major pathways recently shown to be highly relevant for
transducing the mitogenic effect of this polypeptide mitogen,
namely phosphatidylinositol 3-kinase (PI 3-K), extracellular
signal regulated kinase (ERK), and changes in intracellular
calcium concentration ([Ca2+],).
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Methods
Reagents
Monoclonal, agarose-conjugated antiphosphotyrosine anti-
bodies were purchased from Oncogene Science (Uniondale, NY,
U.S.A.). Rabbit antisera against extracellular-signal regulated
kinase (ERK) were kindly donated by Dr M.J. Dunn (Medical
College of Wisconsin, U.S.A.). The antisera recognised both
ERK-l and ERK-2 (Wang et al., 1994). Phosphatidylinositol,
and myelin basic protein were purchased by Sigma Chemical Co.
(St. Louis, MO, U.S.A.). Protein A-sepharose was from Phar-
macia (Uppsala, Sweden). [y-32P]-ATP (3000 Ci mmol-1) and
[(X-32P]-dCTP (3000 Ci mmol-1) were from New England Nu-
clear (Boston, MA, U.S.A.). Human recombinant PDGF-AA, -
AB and -BB were purchased from Boehringer Mannheim
(Mannheim, Germany). Highly purified pentoxifylline was
kindly provided by Dr G. Rinaldi (Hoechst Italia S.p.A., Milan,
Italy). All other reagents were of analytical grade.
Isolation and culture of human HSCs
Human HSCs were isolated from wedge sections of normal
human liver unsuitable for transplantation as previously re-
ported (Pinzani et al., 1992b; Casini et al., 1993). Briefly, after
a combined digestion with collagenase/pronase, HSCs were
separated from other liver nonparenchymal cells by ultra-
centrifugation over gradients of stractan (Larex-LO, Larex
International Co., Tacoma, WA, U.S.A.). Extensive char-
acterization was performed as described elsewhere (Casini et
al., 1993). Cells were cultured on plastic culture dishes (Falcon,
Becton Dickinson, Lincoln Park, NJ, U.S.A.) in Iscove's
modified Dulbecco's medium supplemented with 0.6 u ml-'
insulin, 2.0 mmol I' glutamine, 0.1 mmol 1' nonessential
amino acids, 1.0 mmol I' sodium pyruvate, antibiotic anti-
fungal solution (all provided by Gibco Laboratories, Grand
Island, NY, U.S.A.) and 20% foetal bovine serum (Imperial
Laboratories, Andover, U.K.). Experiments described in this
study were performed on cells between first and fifth serial
passages (1: 3 split ratio) using three independent cell lines. As
already reported (Casini et al., 1993), in our culture conditions,
human HSCs showed transmission electron microscopy fea-
tures of 'transitional cell' (smooth cell surface with slender
nucleus, flattened profiles of rough endoplasmic reticulum in-
terposed among numerous lipid droplets) during the early
phases of subculture (passages 1 and 2), whereas features of
'myofibroblast-like cell' were clearly predominant after the
third serial subculture (passages 3 - 5). These phenotypical
changes are currently considered analogous to those observed
in vivo following chronic liver injury (Mak & Lieber, 1988).
DNA synthesis
DNA synthesis was measured as the amount of [methyl-3H]-
thymidine ([3H]-TdR) incorporated into trichloroacetic acid-
precipitable material. Cells were plated in 24-well dishes at a
density of 2 x 104 cells/well in complete culture medium con-
taining 20% FBS. Confluent cells (approximately 1 x I05 cells/
well) were made quiescent by incubation in SFIF medium for
48 h. Unless otherwise specified, cells were incubated with or
without agonists at the indicated doses and modalities for 20 h
and then pulsed for an additional 4 h with 1.0 1iCi ml-' [3H]-
TdR (6.7 Ci mmol-') (New England Nuclear, Boston, MA,
U.S.A.). At the end of the pulsing period, [3H]-TdR in-
corporation into cellular DNA was measured as previously
reported (Pinzani et al., 1989). Cell number was determined in
three separate wells from each dish and results were expressed
as c.p.m./105 cells.
Cell growth assay
Human HSCs were plated in 12-well dishes at a density of
2 x 104 cells/well in complete culture medium. After 24 h cells
were washed twice with SFIF medium and were placed in the
same medium containing PDGF-BB (10 ng ml-') with or
without PTF (170 gM) pretreatment (Day 0). Cell counts were
performed on quadruplicate wells at Day 0 and after 2, and 4
days by trypsinizing the cells and using a Coulter counter
(Coulter Electronics Inc., Hialeah, FL). Fresh SFIF medium
containing PDGF with or without pretreatment with PTF at
the same concentrations was added to the remaining wells at
each time point. Results are expressed as absolute cell number
at each day of observation.
Phosphatidylinositol 3-kinase (PI 3-K) assay
Confluent HSCs were incubated in SFIF medium for 48 h,
and then treated as indicated in the Results section. They
were quickly placed on ice and washed with ice-cold PBS.
The cell monolayer was lysed in RIPA buffer (composition
mM: Tris-HCl 20, pH 7.4, NaCl 150, EDTA 5, Nonidet P-40
1%, Na3VO4 1, phenyl methyl sulphonyl fluoride (PMSF) 1,
[w/v] aprotinin 0.05%). Insoluble proteins were discarded by
high-speed centrifugation at 4°C. Protein concentration in the
supernatant was measured in triplicate using a commercially
available assay (Bio Rad, Hercules, CA, U.S.A.). PI 3-K
assay was performed as described elsewhere (Ghosh
Choudhury et al., 1991). Briefly, identical amounts of protein
were immunoprecipitated with antiphosphotyrosine anti-
bodies. After washing, the immunobeads were resuspended in
50 l1 of 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM
EGTA; 0.5 pl of phosphatidylinositol (20 mg ml-') was ad-
ded, and the samples were incubated at 25°C for 10 min. One
p1 of 1 M MgCl2 and 10 yuCi of [y-32P]-ATP were added si-
multaneously, and the incubation was continued for an ad-
ditional 10 min. The reaction was stopped by addition of
150 pl of chloroform/methanol/37% HCl 10: 20: 0.2. Samples
were extracted with chloroform and dried. Radioactive lipids
were separated by thin-layer chromatography and developed
with chloroform/methanol/30% ammonium hydroxide/water
46: 41: 5: 8. After drying, the plates were subjected to auto-
radiography. Identity of the 3-OH phosphorylated lipids after
separation by thin-layer chromatography had been previously
assessed by high-pressure liquid chromatography (Ghosh
Choudhury et al., 1991). The radioactive spots were finally
scraped and counted.
ERK assay
ERK was measured as the myelin basic protein kinase activity
of ERK immunoprecipitates. RIPA lysates (60 pg of protein)
obtained as described above were immunoprecipitated with
rabbit polyclonal anti-ERK antibodies and protein A sephar-
ose. After washing, the immunobeads were incubated in a
buffer containing (mM): HEPES 10, pH 7.4, MgCl2 20, di-
thiotreitol 1, Na3VO4 1, [y-32P]-ATP 1 mCi and myelin basic
protein 0.5 mg ml-' for 30 min at 30°C. At the end of the
incubation, 15 ml of the reaction were spotted onto phos-
phocellulose disks, washed four times in 1% phosphoric acid,
and the radioactivity counted in a beta-counter. Another ali-
quot (10 ml) of the reaction mixture was run on 15% SDS-
PAGE. After electrophoresis, the gel was dried and subjected
to autoradiography.
Western blotting
Identical amounts of protein (15-25 pg) were separated by
7.5% or 12% SDS-PAGE, as appropriate, and electro-
blotted on a polyvinylidendifluoride membrane. The mem-
branes were blocked overnight with 2% bovine serum
albumin in 0.1% PBS-Tween, and sequentially incubated at
room temperature with primary and then horseradish per-
oxidase-conjugated secondary antibodies (Amersham, Ar-
lington Heights, IL, U.S.A.). Detection was carried out
using chemiluminescence according to the manufacturer's
protocol (Amersham).
1118
M. Pinzani et al Pentoxifylline effects on PDGF signalling
Northern blot analYsis
RNA was isolated according to Chomczynski & Sacchi (1987).
Ten mg of total RNA were fractionated by I1% agarose-for-
maldehyde gel electrophoresis, and blotted on a nylon mem-
brane. Procedures for DNA radiolabelling and filter
hybridization have been described elsewhere (Marra et al.,
1993).
delayed addition of PTF (10 min after PDGF) did not cause a
significant reduction of the PDGF-induced increase in DNA
synthesis. These observations were confirmed with doses of
PDGF-BB ranging from 1.0 to 10 ng ml-'. As shown in Figure
1, preincubation of cell monolayers with PTF caused a dose-
dependent reduction of the increase in DNA synthesis induced
by PDGF-AA, PDGF-AB and PDGF-BB. PTF inhibited
PDGF-BB-induced DNA synthesis with an IC50 (50% in-
Digital video imaging of intracellular free calcium
concentration in individual human HSCs
Digital video imaging of intracellular free calcium concentra-
tion ([Ca>-],) in individual human HSCs was performed as
described by Pinzani et al. (1992b) and Failli et al. (1995).
Human HSCs were grown till subconfluence in complete cul-
ture medium on round glass cover slips (25 mm diameter,
0.2 mm thick) for 72 h, and then incubated for 48 h in SFIF
medium. Cells were then loaded with 10 yM Fura-2-AM
(Calbiochem Corp., San Diego, CA, U.S.A.), 15% Pluronic F-
127 for 30 min at 22-C. [Ca>-], was measured in Fura-2-loaded
cells in HEPES-NaHCO3 buffer containing (mM): NaCl 140,
KC1 3, NaH2PO4 0.5, NaHCO, 12, MgCI2 1.2, CaCl, 1.0,
HEPES 10 and glucose 10, pH 7.4. Ratio images (340,380 nm)
were collected every 3 s and calibration curves were obtained
for each cell preparation as described by Pinzani et al. (1992b).
PDGF-BB (10 ng ml-') was added directly to the perfusion
chamber immediately after recording the [Ca'>]i basal value.
In parallel experiments, cells were preincubated with PTF
(170 jiM) for 15 min before the addition of PDGF-BB.
Assay of intracellular cyclic AMP levels
Confluent HSCs in 22 mm well dishes were incubated in ser-
um-free insulin-free (SFIF) medium for 24 h. SFIF medium
was then removed and replaced with 200 jil well of a buffer
containing 0.025 M Tris-HCl, 0.25 M sucrose, 0.5% BSA,
pH 7.4. Increasing doses of PTF were added to the wells and
cells were incubated at 37"C for the indicated time points. The
reaction was stopped by the addition of 500 jul of 100% ice-
cold ethanol and dishes were placed at - 20WC for at least 24 h.
Samples were then centrifuged at 2500 g at 4"C for 20 min and
supernatants were collected, lyophilized, and reconstituted
with sodium acetate buffer (50 mM), pH 6.2. Intracellular
adenosine 3': 5'-cyclic monophosphate (cyclic AMP) levels
were measured by RIANEN cyclic AMP [1251] Radio-
immunoassay Kit (Du Pont Company, Billerica, MA, U.S.A.)
according to the instructions provided by the manufacturer.
Cell number was determined in three separate wells from each
dish after trypsinization and counting.
Statistical analysis
Results, relative to the number of experiments indicated, are
expressed as means + s.d. Statistical analysis was performed by
one-way ANOVA and when the F value was significant, by
Duncan's test.
Results
Effect of PTF on the increase in DNA synthesis and cell
proliferation induced by different PDGF dimeric forms in
human HSCs
The effect of PTF on PDGF-induced DNA synthesis, mea-
sured as [3H]-TdR incorporation into DNA, was first eval-
uated. In a preliminary set of experiments, PTF was able to
reduce significantly the increase in DNA synthesis induced by
PDGF dimeric forms only when cells were preincubated with
PTF for 10- 15 min before the addition of PDGF. Conversely,
either the simultaneous addition of both compounds or the
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Figure 1 Effect of pentoxifylline (PTF) pretreatment on DNA
synthesis induced by different PDGF dimeric forms in human hepatic
stellate cells. Dose-response for the effect of increasing concentrations
of PTF on DNA synthesis, evaluated as [3H]-thymidine incorporation
into DNA. induced by different PDGF dimeric forms. Confluent cells
were made quiescent by maintaining them in serum-free,insulin-free
medium for 48 h. Cells were then pretreated for 10- 15 min with
increasing concentrations of PTF before starting an incubation with
fixed doses of (a) PDGF-AA (20 ng ml - l), (b) PDGF-AB
(20ngml-'), (c) PDGF-BB (lOngml-'), for a total of 24h. Cells
were pulsed with [3H]-thymidine during the last 4 h of incubation (see
Methods for details). C, in each panel, refers to control untreated
wells. Data are means + s.d. for five experiments performed in
triplicate. When compared to the effect of PDGF isoforms alone
(PTF concentration = 0 JM), changes were statistically significant
(P<0.05 or higher degree of significance) starting at PTF 350 JIM
for PDGF-AA, PTF 170pM for PDGF-AB and 35AM for PDGF-
BB.
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hibitory concentration) of approximately 170 pM. Because of
the more relevant effect of PTF on PDGF-BB-induced DNA
synthesis, the following experiments were focused on the bio-
logical effects and signalling elicited by this PDGF dimeric
form. In addition, in all the following experiments a standard
dose of PTF (170 yM) was consistently used.
Growth curve experiments for human HSCs in response to
PDGF-BB with or without PTF were performed to demon-
strate whether or not the decrease in PDGF-induced increase
in [3H]-TdR incorporation into DNA is associated with an
actual decrease of cell growth. As shown in Figure 2, PDGF-
BB at a dose of 10 ng ml-', significantly increased HSC
growth after 2 and 4 days of incubation when compared with
unstimulated control cells (P<0.001). This effect was clearly
reduced by pretreating the cells with PTF before the addition
of PDGF, and this reduction was already statistically sig-
nificant after 2 days of culture.
Effect of PTF on PDGF-receptor autophosphorylation
Experiments were performed to elucidate at which step in
PDGF mitogenic signalling the inhibitory effect ofPTF occurs.
Upon binding to PDGF, the receptor increases its tyrosine
kinase activity and 'autophosphorylates'. As shown in Figure 3
(results of one representative experiment out of three), in-
cubation with PDGF-BB resulted in a marked increase in
tyrosine phosphorylation of the receptor (190 kDa band) (lane
3) when compared to control (lane 1). Preincubation of cells
with PTF did not reduce the extent of receptor phosphoryla-
tion (lane 4). Incubation with PTF alone did not induce any
effect on PDGF-R autophosphorylation (lane 2).
Effect ofPTF on the increase of PI 3-K activity induced
by PDGF-BB
The effect of PTF preincubation on the PDGF-induced acti-
vation of PI 3-K was then evaluated. As shown in Figure 4,
(results of one representative experiment out of two) little or
no PI 3-K activity was detectable in unstimulated, serum-
starved HSCs (lane 1). Incubation with PDGF-BB
4.0 -
3 3.0-
0
x 2.0-
0
1.0 -~
(10 ng ml-') remarkably increased the PI 3-K activity asso-
ciated with phosphotyrosine immunoprecipitates (lane 3).
Pretreatment with PTF did not result in a detectable reduction
of this activity (lane 4). Incubation with PTF alone (lane 2) did
not affect PI 3-K activity when compared to unstimulated cells.
Effect of PTF on PDGF-stimulated extracellular signal-
regulated kinase (ERK) activity in human HSCs
Exposure of serum-deprived HSCs to PDGF-BB resulted in
ERK activation after 5 min of incubation with a peak at 10-
15 min (data not shown). As illustrated in Figure 5a (results of
one representative experiment out of three), incubation for
10 min with PDGF-BB (10 ng ml-') induced a remarkable
increase in ERK activity as indicated by MBP kinase activity
of ERK immunoprecipitates (lane 3). Preincubation with PTF
for 10-15 min before the addition of PDGF resulted in
complete prevention of PDGF-stimulated ERK activity (lane
4). PTF alone (lane 2) did not affect ERK activity of un-
stimulated HSCs (lane 1). As shown in Figure 5b (one re-
presentative experiment out of three), exposure of HSCs to
PDGF-BB (10 ng ml-') resulted in a slower electrophoretic
mobility of the two ERK isoforms, i.e. ERK-1 and ERK-2,
indicating phosphorylation of tyrosine and/or threonine re-
sidues (lane 2). Preincubation with PTF for 10-15 min before
stimulating the cells with PDGF (lane 4) resulted in a marked
reduction of the amount of protein shifted upward, indicating
reduced phosphorylation of both ERK isoforms. Importantly,
the effects of PTF on both ERK activity and ERK isoform
phosphorylation were not observed when. cells were pre-
incubated with PTF for time periods shorter than 10 min (data
not shown).
Effect of PTF on PDGF-induced c-fos mRNA
expression in human HSCs
The effects of PTF on PDGF-induced increase in c-fos mRNA
expression, as a downstream target of ERK activation, were
then evaluated. As shown in Figure 6 (results of one re-
presentative experiment out of three), c-fos mRNA expression,
not detectable in baseline conditions as well as 15 min after the
addition of PDGF, was clearly evident after 30 min. Pre-
PDGF-BB - - + +
PTF _ + _ +
*
-200 kD
0 2 4
Days in culture
Figure 2 Effect of pentoxifylline (PTF) pretreatment on PDGF-BB-
induced cell proliferation in human hepatic stellate cells. Human
HSCs were plated in 12 well-dishes at the density of 0.4 x 105 cells per
well in complete culture medium. After 24h (Day 0) cells were
washed twice with serum-free/insulin-free medium and then incubated
in fresh serum-free/insulin-free medium alone (control, 0) or
containing either PDGF-BB (0) or PTF plus PDGF-BB (U). At
each time point (Day 2 and Day 4), cells were trypsinized and
counted with a Coulter cell counter. Fresh medium containing the
same test conditions was added to the remaining wells at each time
point. PTF (170yM) was always added 10-15 min before the
addition of PDGF-BB (lOngml-F). Data (mean±s.d.), expressed
as the absolute cell number, are from two experiments done in
quadruplicate. *P<0.005 or higher degree of significance when
compared to cells preincubated with PTF.
-116 kD
1 2 3 4
Figure 3 Effect of pentoxifylline (PTF) on PDGF receptor autopho-
sphorylation in human hepatic stellate cells. Confluent human HSCs
were maintained for 48 h in serum-free/insulin-free medium and then
pretreated with PTF (170pm; lanes 2 and 4) for 15min before a
10min incubation with PDGF-BB (lOngml- 1; lanes 3 and 4); 20pg
of cell lysate was separated by 7.5% SDS-PAGE and blotted with
anti-phosphotyrosine antibodies. Representative experiment out of
three.
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treatment of cells with PTF resulted in an almost complete
abrogration of c-fos expression, suggesting inhibition of the
nuclear phase of the Ras/ERK pathway. In agreement with
what had been observed previously, the inhibitory effect of
PTF on PDGF-induced c-fos expression was not detectable
when cells were preincubated with PTF for time periods less
than 10 min.
Effect of PTF on PDGF-induced increase in [Ca2+]i
As shown in Figure 7, in individual Fura-2-loaded human
HSCs, PDGF addition (open circles, average of 25 in-
dependent determinations in individual cells) caused the oc-
currence of an earlier cell synchronous CaQ2+ spike (mean
[Ca2+]i at the peak 660 nM, n = 25) over an average basal
[Ca2+], of 70 nM. The peak phase was then followed by a long-
lasting plateau (mean [Ca2+]i 304 nM). Preincubation with
PTF (170 gM) for 15 min before the addition of PDGF (solid
squares, average of 25 independent determinations in in-
dividual cells), caused a marked reduction of both the peak
and the plateau phase of [Ca2+], increase. For each single
point, the standard deviation did not exceed 15% of the mean
value.
cyclic AMP levels with an EC50 of approximately 170 gM (dose
range 35-1700 Mm) within a 10-20 min time-range. Subse-
quently, time-course experiments, performed with PTF
170 gM, indicated a peak effect at 10 min with significantly
increased levels persisting for at least 30 min after the addition
of the drug (Figure 8).
No apparent differences were seen in the effects of PTF on
PDGF-induced cell proliferation and intracellular signalling
between different cell lines and different stages of activation in
culture (passages 1-5).
Discussion
In addition to its proposed actions on defective regional mi-
crocirculation, PTF has recently been indicated as a potential
antiinflammatory/immunomodulator and antifibrogenic agent.
Concerning this latter effect, the bulk of the available experi-
mental evidence is so far limited to sound studies performed on
dermal fibroblasts (Berman et al., 1989; Chang et al., 1993;
Duncan et al., 1995), in which, however, very little attention
has been paid to an important aspect of fibrogenesis, namely
Effect of PTF on intracellular cyclic AMP levels in
human HSCs
The following experiments were performed in order to verify
whether or not: (a) PTF was able to induce changes in cyclic
AMP levels in HSCs, and (b) these changes could help to ex-
plain the 10- 15 min preincubation period required to observe
the effects on PDGF-induced mitogenesis and signalling. In a
preliminary set of experiments, PTF increased intracellular
a
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Figure 4 Effect of pentoxifylline (PTF) Qn PDGF-induced phos-
phatidylinositol 3-kinase (PI 3-K) in human stellate cells. Confluent
human HSCs were maintained for 48 h in serum-free/insulin-free
medium and then pretreated with PTF (170pm; lanes 2 and 4) for
15 min before a 10min incubation with PDGF-BB (10 ngml- 1; lanes
3 and 4). Cell lysates were immunoprecipitated with antipho-
sphotyrosine antibodies and PI 3-K assay was performed as described
in Methods. (a) Shows autoradiography of [32P]-phosphatidylinositol-
3-phosphate. The radioactive spots were scraped and counted in a
beta-counter, as shown in (b). Representative experiment of two.
_ p44ERK-1
p42ERK-2
1 2 3 4
Figure 5 Effect of pentoxifylline on PDGF-induced extracellular
signal-regulated kinase (ERK) activity and phosphorylation in
human stellate cells. Confluent HSCs, maintained for 48 h in
serum-free/insulin-free medium, were incubated as detailed in Figure
4. (a) Cell lysates (60yg of protein) were immunoprecipitated with
polyclonal anti-ERK antibodies, and the immunobeads were assayed
for myelin basic protein (MBP) kinase activity as indicated in
Methods. The upper part of the figure shows phosphorylated MBP
after running on 15% SDS-PAGE, whereas the lowest part shows
counts after spotting the reaction mix on phosphocellulose discs and
extensive washings. Representative experiment out of three. (b)
Twenty yg of cell lysate were separated by 12% SDS-PAGE and
blotted with polyclonal anti-ERK antibodies. As shown in lane 2,
addition of PDGF-BB caused a reduced electrophoretic mobility of
both ERK-1 and ERK-2. Preincubation with PTF before the
addition of PDGF induced a complete abrogation of this effect (lane
4). Representative experiment out of three.
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Figure 6 Effect of pentoxifylline (PTF) on PDGF-induced expres-
sion of c-fos mRNA. Confluent human HSCs were maintained for
48 h in serum-free/insulin-free medium and then incubated with
PDGF-BB (10 ngml-), with or without a 15min preincubation with
PTF (170Mm), for the indicated time points. RNA purification and
hybridization were carried out as detailed in Methods. Control (C)
refers to RNA isolated from cells incubated for 48 h in serum-free/
insulin-free medium alone. c-fos cDNA probe was then removed by
boiling, and the same blot hybridized to a cDNA encoding for the
ribosomal protein 36B4 (control gene). Representative experiment of
two.
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Figure 7 Effect of entoxifylline (PTF) on PDGF-induced increase
in intracellular Ca2 concentration ([Ca2+ ]j) in individual Fura-2-
loaded human hepatic stellate cells. Subconfluent (70-80% con-
fluent) HSCs were maintained in serum-free/insulin-free medium for
48 h and were then loaded with Fura-2-AM as indicated in Methods.
PDGF-BB (lOngmP-') was added at the arrow. The two tracings
illustrate the changes in [Ca21], induced by PDGF with (0) or
without (i) a 15min preincubation with PTF 50igmF-1. Data are
the mean of 25 determinations in individual cells stimulated with
PDGF compared with an identical number of cells pretreated with
PTF. For each single point, standard deviation did not exceed 15%
of the mean value. Measurements were obtained at 3 s time intervals.
the proliferation of ECM-producing cells and their relation-
ship with polypeptide mitogens potentially involved in this
process. Along these lines, the report by Peterson (1993), de-
scribing a dose-dependent reduction of PDGF-induced DNA
synthesis by PTF in dermal fibroblasts, still constitutes the
only available piece of experimental evidence. Therefore, stu-
dies specifically addressing this issue in other cell types in-
volved in fibrogenic disorders and dissecting the molecular
mechanisms of the antiproliferative effects of PTF are espe-
cially required.
The results of the present study indicate that PTF dose-
dependently reduces the mitogenic effect of PDGF isoforms
employed at saturating concentrations (Pinzani et al., 1995).
Although an inhibitory effect was observed for all PDGF di-
meric forms, it was remarkably more relevant for PDGF-BB
due to its well-established higher mitogenic potential for HSCs
(Pinzani et al., 1991; 1995), a cell type primarily involved in the
progression of hepatic fibrosis. As demonstrated by cell pro-
liferation experiments, the inhibitory effect of PTF does not
appear to be limited to PDGF-induced increase in DNA
synthesis, but it is also directed to an effective inhibition of cell
proliferation. Subsequently, the potential effects ofPTF on the
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Figure 8 Effect of pentoxifylline on intracellular cyclic AMP levels
in human hepatic stellate cells. Time-course for the effect of
pentoxifylline (170uM) on intracellular cyclic AMP levels. Confluent
cells were incubated in serum-free/insulin-free medium for 48h and
then stimulated with pentoxifylline for the indicated time points.
Intracellular cyclic AMP levels were measured as detailed in
Methods. Data are means+s.d. for three experiments performed in
quadruplicate. *P<0.005 or higher degree of significance when
compared to unstimulated cells (time 0).
main signalling pathways elicited by the autophosphorylation
of the PDGF receptor and leading to mitogenesis were eval-
uated.
After observing that PTF does not affect the extent of
PDGF receptor autophosphorylation, its possible effects on PI
3-K activity were studied. PI 3-K is a lipid and protein kinase
which associates with the PDGF-receptor and other tyrosine
kinases (Parker & Waterfield, 1992). The signals generated by
PI 3-K are only partially known, but this pathway has been
shown to be sufficient to transduce a PDGF-dependent mito-
genic signal (Valius & Kaslauskas, 1993), and accordingly, it
has been recently demonstrated that PI 3-K activation con-
stitutes an important pathway involved in PDGF-induced
mitogenesis in human HSCs (Marra et al., 1995a,b). However,
the results of the experiments described in the present paper
clearly indicated that PTF is unable to affect the activation of
this PDGF-stimulated pathway, thus ruling out a possible
modulatory effect at this level.
The potential effects of PTF on another series of in-
tracellular signalling events, namely the Ras/ERK pathway,
the activation of which has been shown to be an absolute re-
quirement for triggering growth factor-mediated proliferative
responses (Pages et al., 1993), were subsequently studies. Ac-
tivated Ras triggers a kinase cascade, with sequential activa-
tion of Raf-1, MEK and ERK (Marshall, 1995). ERK belongs
to the family of mitogen-activated protein kinases (MAP-K).
Two isoforms have been identified so far and are referred to as
ERK-I (or p44M'K) and ERK-2 (or p42MAPK). The results of
these experiments indicate that PTF induces a remarkable
decrease of PDGF-stimulated ERK activity in human HSCs,
and that this effect is probably related to a reduced phos-
phorylation of both ERK isoforms. Along these lines, several
recent studies have clearly shown that agents able to elevate
intracellular cyclic AMP levels may reduce cell growth via in-
hibition of RAF kinase which operates as an upstream reg-
ulator of ERK (Burgering et al., 1993; Cook & McCormick,
1993). This action has been suggested to occur through cyclic
AMP-activated protein kinase A (PKA) phosphorylation of
Raf-l (Wu et al., 1993; Graves et al., 1993). It is therefore
conceivable that, also in the cellular model employed in the
present study, the dose-dependent increase in intracellular
cyclic AMP levels induced by PTF, due to inhibition of cyclic
nucleotide phosphodiesterases (Stefanovich et al., 1974), and
the subsequent activation of PKA are responsible for the in-
activation of the Ras/ERK pathway elicited by PDGF. In-
direct evidence supporting this hypothesis derives from the
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lack of detectable effects on the PDGF-induced phosphoryla-
tion of ERK subunits and ERK activity in experiments where
incubation with PTF was not performed for the minimum time
period of 15 min necessary to elicit a significant increase in
intracellular cyclic AMP levels, and from the coincidence ob-
served between the EC50 for PTF-induced increase in in-
tracellular cyclic AMP levels and the IC50 for the inhibitory
effect of PTF on PDGF-BB-induced mitogenesis.
In mammalian cells, the Ras/ERK pathway directs signals
to the serum response element of c-fos and other co-regulated
genes. The results of the experiments showing an inhibition of
PDGF-induced c-fos expression by PTF further supports an
effect of this drug on the activated Ras/ERK pathway, in-
cluding downstream nuclear events leading to cell prolifera-
tion. However, although these results are consistent with a
model in which PTF-induced increase in cyclic AMP levels
inhibits PDGF-stimulated growth by inhibiting Raf activation,
the possibility that the increase in cyclic AMP may affect cell
growth through Raf-independent mechanisms cannot be ex-
cluded. Indeed it is well-established that the expression of
cyclic AMP-responsive genes, including c-fos, can be directly
regulated through phosphorylation of transcription factors by
catalytic subunits of cyclic AMP-activated PKA (Lalli & Sas-
sone-Corsi, 1994; Roesler et al., 1995).
Studies from this laboratory have indicated that stimulation
of confluent HSCs with PDGF-BB is associated with an in-
crease in [Ca2+]i (Pinzani et al., 1991; Failli et al., 1995). This
effect is characterized by two main components: (1) a con-
sistent and transient increase (peak increase), probably related
to Ca2+ release from internal stores, and (2) a lower but longer
lasting increase (plateau phase) due to an influx from the ex-
ternal medium. The results of the present study indicate that
preincubation of quiescent human HSCs with PTF for a suf-
ficient period of time causes an almost complete abrogation of
both the peak and the plateau phase of the [Ca2+]i increase
induced by PDGF. Analogous to what was concluded for the
action of PTF on the Ras/ERK pathway, this effect could be
due to the increase in intracellular cyclic AMP levels induced
by PTF. Accordingly, an increase in intracellular cyclic AMP
levels has been shown to reduce [Ca2']i by inhibiting Ca2"
influx or by activating Ca2+ sequestration (Furukawa et al.,
1988; Cooper et al., 1995). Importantly, induction of re-
plicative competence by PDGF in this cell type has been shown
to be greatly influenced by the maintenance of the plateau
phase of [Ca2+], increase (Failli et al., 1995), although it is
presently unclear at which level, in the cascade of intracellular
signalling events elicited by PDGF and leading to cell pro-
liferation, this phenomenon could play a role. This aspect, that
certainly deserves further attention, may involve a direct or
indirect effect of [Ca2+], on ERK stimulation as suggested by
studies highlighting the existence of at least two independent
pathways for the activation of this system: one that is depen-
dent on intracellular calcium mobilisation, and one that is
mediated by receptor tyrosine kinase and is calcium-in-
dependent (Chao et al., 1992).
In conclusion, the observations reported here indicate that
PTF, in addition to its effects on collagen deposition and de-
gradation, may exert an antifibrogenic effect by reducing the
PDGF-induced proliferation of extracellular matrix producing
cells. This effect appears mediated by a reduction of PDGF-
stimulated ERK activity as well as of other intracellular sig-
nalling pathways such as the PDGF-induced elevation of cy-
tosolic-free calcium. Although the inhibitory effects of PTF
were clearly detected only at high concentrations (above
10'- M), these observations provide additional cellular and
molecular basis for the development of phosphodiesterase in-
hibitors with higher bio-availability and selectivity to be em-
ployed in the treatment of organ-specific as well as systemic
fibrogenic disorders.
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